Study of two targeted therapies before surgery for HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have been diagnosed with HER2-positive breast cancer (confirmed by a special test).
- Your breast cancer is stage II or III but has not spread to other parts of the body.
- You have not had any previous treatment (like chemotherapy or radiation) for this cancer.
- You are generally healthy and able to do normal activities (ECOG score 0 or 1).
- You are not pregnant or nursing, and you agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial compares two drugs, trastuzumab rezetecan and trastuzumab deruxtecan, given before surgery to shrink HER2-positive breast cancer tumors. It aims to see which drug works better and has fewer side effects, potentially offering a more effective treatment option for patients.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This study tests whether giving two drugs (SHR-A1811 and pertuzumab) before surgery can shrink HER2-positive breast cancer tumors. It aims to see if this combination improves treatment outcomes for patients with stage II or III disease.
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.